Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease.
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease.
复制标题
DOI：
10.1038/s41598-021-96294-8
复制
发表时间：
2021-08-19
影响因子：
4.6
通讯作者：
Tamura K
中科院分区：
文献类型：
--
作者：
Tsukamoto S;Wakui H;Azushima K;Yamaji T;Urate S;Suzuki T;Abe E;Tanaka S;Taguchi S;Yamada T;Kinguchi S;Kamimura D;Yamashita A;Sano D;Nakano M;Hashimoto T;Tamura K
作为严重急性呼吸综合征冠状病毒2型潜在靶点的器官中血管紧张素转换酶2（ACE 2）表达升高可能会增加2019冠状病毒病（COVID-19）感染的风险。先前的报道表明，ACE 2在包括肾脏疾病在内的各种病理条件下改变其组织特异性表达模式。在这里，我们研究了两种小鼠慢性肾病（CKD）模型中肺ACE 2表达的变化：腺嘌呤诱导的（腺嘌呤小鼠）和马兜铃酸诱导的（AA小鼠）。我们还研究了这些小鼠中由于肾素-血管紧张素系统（RAS）阻断剂（奥美沙坦）治疗引起的肺ACE 2表达的变化。与对照组相比，腺嘌呤小鼠表现出显著的肾功能下降和血压升高。与溶媒组相比，AA小鼠还显示出显著的肾功能下降;两组之间的血压没有差异。腺嘌呤小鼠和AA小鼠的肾脏ACE 2表达显著降低;肺表达不受影响。奥美沙坦减弱腺嘌呤小鼠的尿白蛋白排泄，但不影响肾脏或肺ACE 2表达水平。结果表明，CKD患者的COVID-19感染风险可能不会升高，因为他们的肺部ACE 2表达稳定。此外，RAS阻断剂可安全用于治疗COVID-19伴CKD患者。
Elevated angiotensin-converting enzyme 2 (ACE2) expression in organs that are potential targets of severe acute respiratory syndrome coronavirus 2 may increase the risk of coronavirus disease 2019 (COVID-19) infection. Previous reports show that ACE2 alter its tissue-specific expression patterns under various pathological conditions, including renal diseases. Here, we examined changes in pulmonary ACE2 expression in two mouse chronic kidney disease (CKD) models: adenine-induced (adenine mice) and aristolochic acid-induced (AA mice). We also investigated changes in pulmonary ACE2 expression due to renin–angiotensin system (RAS) blocker (olmesartan) treatment in these mice. Adenine mice showed significant renal functional decline and elevated blood pressure, compared with controls. AA mice also showed significant renal functional decline, compared with vehicles; blood pressure did not differ between groups. Renal ACE2 expression was significantly reduced in adenine mice and AA mice; pulmonary expression was unaffected. Olmesartan attenuated urinary albumin excretion in adenine mice, but did not affect renal or pulmonary ACE2 expression levels. The results suggest that the risk of COVID-19 infection may not be elevated in patients with CKD because of their stable pulmonary ACE2 expression. Moreover, RAS blockers can be used safely in treatment of COVID-19 patients with CKD.
登录
查看更多内容
影响因子：
5.3
作者：
Nägele MP;Haubner B;Tanner FC;Ruschitzka F;Flammer AJ
通讯作者：
Flammer AJ
DOI：
10.1152/ajprenal.00426.2009
发表时间：
2010-06-01
影响因子：
4.2
作者：
Dilauro, Marc;Zimpelmann, Joseph;Burns, Kevin D.
通讯作者：
Burns, Kevin D.
影响因子：
3.8
作者：
Braga, Aecio A.;Bortolin, Raul H.;Hirata, Mario H.
通讯作者：
Hirata, Mario H.
影响因子：
5.4
作者：
Iwanami, Jun;Mogi, Masaki;Horiuchi, Masatsugu
通讯作者：
Horiuchi, Masatsugu
影响因子：
64.8
作者：
Imai Y;Kuba K;Rao S;Huan Y;Guo F;Guan B;Yang P;Sarao R;Wada T;Leong-Poi H;Crackower MA;Fukamizu A;Hui CC;Hein L;Uhlig S;Slutsky AS;Jiang C;Penninger JM
通讯作者：
Penninger JM